MBX-2982 is a potential first-in-class treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.
More Information Supplier PageMBX-2982 is a potential first-in-class treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.
More Information Supplier PageMK-3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists.
More Information Supplier PageMK-3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists.
More Information Supplier PageCombretastatin A4 is an antitumor, antiangiogenic and antimetastatic agent, in vitro and in vivo. Inhibits tubulin polymerization.
More Information Supplier PageCombretastatin A4 is an antitumor, antiangiogenic and antimetastatic agent, in vitro and in vivo. Inhibits tubulin polymerization.
More Information Supplier PageCombretastatin A4 is an antitumor, antiangiogenic and antimetastatic agent, in vitro and in vivo. Inhibits tubulin polymerization.
More Information Supplier PageCombretastatin A4 is an antitumor, antiangiogenic and antimetastatic agent, in vitro and in vivo. Inhibits tubulin polymerization.
More Information Supplier Pagelorcaserin hydrochloride (APD-356) is a serotonin 2C receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults
More Information Supplier Pagelorcaserin hydrochloride (APD-356) is a serotonin 2C receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults
More Information Supplier Page
